TherapeuticsMD (TXMD) Receives Approval from FDA of sNDA for BIJUVA

January 3, 2022 6:36 AM EST

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

TherapeuticsMD (NASDAQ: TXMD) disclosed:

On December 28, 2021, TherapeuticsMD, Inc., a Nevada corporation (the “Company”), received approval from the U.S. Food and Drug Administration (the “FDA”) on the supplemental New Drug Application for the 0.5 mg/100 mg dose of the Company’s BIJUVA® product. The Company is currently evaluating plans for commercialization of the low dosage BIJUVA® product.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Related Entities

FDA